Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
A pivotal step forward for Duchenne families as gene therapy shows promise to transform neuromuscular care.
A historic breakthrough as the first CRISPR-based gene-editing therapy gains FDA approval, offering new hope for sickle cell …
ExoGene’s novel delivery platform earns RMAT status for its lead candidate EXG-401, targeting neuroinflammation and motor neuron survival …
Already a subscriber? Log in